Tag: Therapeutics

Viking Therapeutics Initiates Pivotal Phase 3 Trial: Here’s Why Investors Have Reason for Optimism After a Disappointing Phase 2

Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It’s Not Too Late to Buy the Stock.

How Much Could $1,000 Invested in Viking Therapeutics Be Worth by 2030?

Don’t Buy Viking Therapeutics Stock Until You Read This

Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares

What’s the Next Big Thing After GLP-1 Drugs? CRISPR Therapeutics May Have the Answer.

CIBRA Capital Makes a Big Merger Arbitrage Bet On Amicus Therapeutics (FOLD)

Got $5,000? Viking Therapeutics Might Be a Weight‑Loss Drug Moon Shot in the Making.

Protagonist Therapeutics Chief Medical Officer Sells PTGX 9,514 Shares for $784K to Cover Taxes

Sionna Therapeutics Chief Legal Officer Caps Off Strong 2025 with Sale of Over 10,000 Shares